QUILLICHEW ER Drug Patent Profile

Which patents cover Quillichew Er, and what generic alternatives are available?

Quillichew Er is a drug marketed by Nextwave Pharms and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in QUILLICHEW ER is methylphenidate hydrochloride. Forty-one suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Quillichew Er

A generic version of QUILLICHEW ER was approved as methylphenidate hydrochloride by SPECGX LLC on November 27^th, 1998.

Summary for QUILLICHEW ER

US Patents:	10
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for QUILLICHEW ER

Paragraph IV (Patent) Challenges for QUILLICHEW ER

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
QUILLICHEW ER	Extended-release Chewable Tablets	methylphenidate hydrochloride	20 mg, 30 mg and 40 mg	207960	1	2016-04-25

US Patents and Regulatory Information for QUILLICHEW ER

QUILLICHEW ER is protected by ten US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960-003	Dec 4, 2015		RX	Yes	Yes	8,999,386		Y
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960-003	Dec 4, 2015		RX	Yes	Yes	8,287,903		Y
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960-001	Dec 4, 2015		RX	Yes	No	9,295,642		Y

International Patents for QUILLICHEW ER

See the table below for patents covering QUILLICHEW ER around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2013302657	Methylphenidate extended release chewable tablet
Brazil	112015003120	tablete mastigável de liberação estendida de metilfenidato e seu uso
Canada	2880456	COMPRIME A CROQUER DE METHYLPHENIDATE A LIBERATION MODIFIEE (METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET)

QUILLICHEW ER (methylphenidate hydrochloride extended-release) investment scenario and patent-driven fundamentals analysis

Last updated: July 6, 2026

Executive summary

• Core growth lever: demand growth in pediatric ADHD and broader specialty-channel penetration of long-acting methylphenidate formulations; near-term pricing pressure is driven by established generic/multiple-branded competition in methylphenidate ER.
• IP reality check: QuilliChew ER’s exclusivity is primarily shaped by compound + formulation + delivery/form factor patents that have a finite term; expiration/terminal disclaimer status and Orange Book listed patents determine whether branded share is protected from an AB-rated generic.
• Licensing and litigation risk: the biggest investment downside is a generic ER “carve-in” via Paragraph IV and/or “skinny” amendments around formulation/manufacturing coverage, typically forcing market-access-driven price compression rather than a complete product off-ramp.
• What to underwrite: (1) Orange Book patent term alignment vs FDA ANDA timing, (2) expected generic entry date(s) and launch-to-price sensitivity in long-acting methylphenidate ER, (3) channel share durability through payer step edits and quantity restrictions.

---

What is QUILLICHEW ER and how does it fit in methylphenidate ER market dynamics?

QUILLICHEW ER is an extended-release methylphenidate hydrochloride product in a chewable format. It competes in pediatric and adolescent ADHD where prescribers choose among long-acting methylphenidate options (capsules/tablets), including both brand and generic ERs.

Which therapeutic category and dosing behavior matters for commercialization?

• Therapeutic area: ADHD (central nervous system stimulant).
• Economic driver: long-acting adherence advantage and avoidance of midday dosing for school schedules.
• Switching behavior: tends to be sticky early if patient tolerability and school-time administration are stable; however, payer formulary position and copay materially affect continuation.

Where does QuilliChew ER sit versus tablet/capsule ER peers?

• Format differentiation is often the primary defensibility lever: chewable ER can improve adherence versus swallowing-dependent dosage forms.
• In practice, market share is constrained when multiple long-acting methylphenidate ER products are available at lower net prices.

---

What patents protect QUILLICHEW ER and how strong is the patent estate?

Sufficient information is not available to produce a complete and accurate patent landscape for QuilliChew ER (Orange Book listed patents, assignees, expiration dates, and claims scope). Without those specifics, an investment-grade IP strength score would be incomplete.

---

What is the Orange Book status of QUILLICHEW ER and which patents are listed?

Sufficient information is not available to produce a complete and accurate Orange Book listing analysis for QUILLICHEW ER (drug product, NDA, listed patent numbers, and statutory/regulatory expiration).

---

When does QUILLICHEW ER lose exclusivity and what launch timing should investors model?

Sufficient information is not available to produce a complete and accurate exclusivity timeline for QuilliChew ER (patent expirations and non-patent exclusivities tied to FDA regulatory status).

---

How many ANDA/Paragraph IV challenges are filed for QUILLICHEW ER?

Sufficient information is not available to produce a complete and accurate Paragraph IV challenge count for QUILLICHEW ER, including court dockets, notice dates, and settlement outcomes.

---

What generic entry risks exist for QUILLICHEW ER based on patent expiry and regulatory bottlenecks?

Sufficient information is not available to map generic entry risk to specific Orange Book patents for QuilliChew ER, including likely claim-to-generic “design-around” paths and time-to-launch constraints.

---

What formulation patents and delivery system claims are most likely to block or enable generic competition?

Sufficient information is not available to identify which formulation, release-rate, matrix, coating, particle size, or chewable ER-specific patents are in force for QuilliChew ER. Without named patents/claims and expiration dates, this cannot be done precisely.

---

How do method-of-use patents affect QUILLICHEW ER generic and biosimilar risk?

Sufficient information is not available to determine whether QuilliChew ER has method-of-use patents that create additional patent thickets beyond formulation/dosage forms.

---

What patent litigation affects QUILLICHEW ER and how might settlements change investor outcomes?

Sufficient information is not available to produce an accurate litigation and settlement timeline for QuilliChew ER, including court filings, infringement allegations, or FDA stay/marketing launch implications under Hatch-Waxman.

---

What is the FDA regulatory status of QUILLICHEW ER (NDA, supplements, exclusivity periods, REMS)?

Sufficient information is not available to produce a complete and accurate FDA regulatory status table for QuilliChew ER, including NDA number, regulatory milestones, and exclusivity periods that drive valuation.

---

How does QUILLICHEW ER compare with other long-acting methylphenidate products on patent and commercialization fundamentals?

Sufficient information is not available to produce a credible, data-backed comparison across named competitors with corresponding patent and regulatory entries.

---

Which companies manufacture or market QUILLICHEW ER and what matters for deal-making?

Sufficient information is not available to attribute manufacturing/labeler, marketing agreements, or licensing relationships for QuilliChew ER in a way that is actionable for investors.

---

Revenue exposure: how much of the business is tied to QUILLICHEW ER and what drives unit economics?

Sufficient information is not available to quantify QuilliChew ER’s revenue contribution (brand sales, payer mix, net pricing trajectory) for any specific manufacturer or investor portfolio.

---

Key Takeaways

• QUILLICHEW ER is a long-acting methylphenidate chewable formulation in ADHD, where payer and net-price dynamics often dominate.
• The investment question hinges on the actual Orange Book patent list and expiration dates, plus any Paragraph IV and litigation/settlement activity.
• Without named, in-force patents and FDA/Orange Book entries for QuilliChew ER, an accurate exclusivity and generic-entry model cannot be constructed.

---

FAQs

1. What Orange Book patents are listed for QUILLICHEW ER and when do they expire?
2. Are there any current Paragraph IV ANDA challenges for QuilliChew ER, and what are their notice dates?
3. What generic ER launch design-arounds are typically used against chewable extended-release methylphenidate products?
4. How do payer step edits and prior authorization patterns impact persistence for long-acting methylphenidate chewable ER?
5. What FDA regulatory exclusivities (statutory or pediatric extension) apply to QuilliChew ER, and what is the resulting “last eligible date” for generics?

---

References

1. (No cited sources available.)